A Phase 3 study of Adjuvant Selpercatinib in lung cancer

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC 

For more information:

https://clinicaltrials.gov/ct2/show/NCT04819100?term=NCT04819100&draw=2&rank=1